This study suggests that, six months after the renal biopsy: 1) The combination of serum C3 levels below normal with normal C4 levels, once inflammatory activity is controlled with immunosuppression, identifies LN patients at high risk of developing CKD and ESKD, and 2) Linear increases in C3 levels reduce independently the same risk. The gene discussed is C4A; the disease is lobular neoplasia.